CN Patent

CN105980559A — 用于抑制alas1基因表达的组合物与方法

Assigned to Xi Naishanyikan Medical College · Expires 2016-09-28 · 10y expired

What this patent protects

本发明涉及靶向ALAS1基因的双链核糖核酸(dsRNA)组合物，和使用这类dsRNA组合物来改变(例如，抑制)ALAS1的表达的方法。

USPTO Abstract

本发明涉及靶向ALAS1基因的双链核糖核酸(dsRNA)组合物，和使用这类dsRNA组合物来改变(例如，抑制)ALAS1的表达的方法。

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

Patent Metadata

Patent number: CN105980559A
Jurisdiction: CN
Classification: —
Expires: 2016-09-28
Drug substance claim: No
Drug product claim: No
Assignee: Xi Naishanyikan Medical College
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.